Nawar R, Aron D
Division of Clinical and Molecular Endocrinology, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Endocr Relat Cancer. 2005 Sep;12(3):585-98. doi: 10.1677/erc.1.00951.
Adrenal incidentalomas (AI), adrenal tumors detected through an imaging procedure done for reasons unrelated to adrenal dysfunction, is becoming a common clinical problem with the more frequent utilization of different imaging techniques. Most such tumors are benign and hormonally inactive. A variety of diagnostic strategies have been developed to distinguish the latter; however, they are still controversial. Even after a commissioned systematic review of the literature and a state of the science conference sponsored by the National Institutes of Health, the optimal strategy for hormonal screening of a patient with AI is unknown, but we anticipate further refinements and major advances in the field. Surgery is the ultimate solution for the diagnostic-therapeutic dilemma of AI. Careful planning is required, and the learning curve which influences clinical decision making is especially relevant to immediate outcomes. The benefit of making a diagnosis of a clinically significant AI must be considered in the context of the patient's overall condition and preferences.
肾上腺偶发瘤(AI)是指在因与肾上腺功能障碍无关的原因而进行的影像学检查中发现的肾上腺肿瘤,随着不同影像学技术的更频繁使用,它正成为一个常见的临床问题。大多数此类肿瘤是良性的且无激素活性。已经开发出多种诊断策略来区分后者;然而,它们仍然存在争议。即使在委托对文献进行系统综述以及由美国国立卫生研究院主办的科学现状会议之后,对肾上腺偶发瘤患者进行激素筛查的最佳策略仍不明确,但我们预计该领域将进一步完善并取得重大进展。手术是解决肾上腺偶发瘤诊断 - 治疗困境的最终方法。需要仔细规划,影响临床决策的学习曲线与近期结果尤其相关。在考虑患者的整体状况和偏好的背景下,必须权衡做出具有临床意义的肾上腺偶发瘤诊断的益处。